Abstract
The HER2/neu (HER2) gene is a member of a family of genes which has been implicated in cancer. These four genes, HER1/EGFR, HER2, HER3 and HER4 encode for transmembrane proteins that are involved in the regulation of cell proliferation, differentiation and survival. Amplification of HER2 occurs in 20%-25% of breast cancers and is associated with an aggressive tumor phenotype and poor prognosis. Results from five randomized, phase III clinical trials have recently demonstrated that trastuzumab (Herceptin®) significantly improves disease free survival and overall survival when used in conjunction with chemotherapy for early stage HER2- positive breast cancer. Despite adjuvant trastuzumab, approximately 15% of patients with early stage disease recur, and those with metastatic disease eventually become resistant to therapy. Novel treatment approaches are needed for patients who have either intrinsic or acquired resistance to trastuzumab. This article reviews the role of trastuzumab in managing early and advanced stage HER2-positive disease, the role of lapatinib (Tykerb®) in trastuzumab resistant disease, and the novel agents in development targeting mechanisms of trastuzumab resistance.
Keywords: chemotherapy, Trastuzumab Trials, docetaxel, Disease Free Survival, Cardiotoxicity, Lapatinib
Reviews on Recent Clinical Trials
Title: Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions
Volume: 2 Issue: 2
Author(s): Rita Nanda
Affiliation:
Keywords: chemotherapy, Trastuzumab Trials, docetaxel, Disease Free Survival, Cardiotoxicity, Lapatinib
Abstract: The HER2/neu (HER2) gene is a member of a family of genes which has been implicated in cancer. These four genes, HER1/EGFR, HER2, HER3 and HER4 encode for transmembrane proteins that are involved in the regulation of cell proliferation, differentiation and survival. Amplification of HER2 occurs in 20%-25% of breast cancers and is associated with an aggressive tumor phenotype and poor prognosis. Results from five randomized, phase III clinical trials have recently demonstrated that trastuzumab (Herceptin®) significantly improves disease free survival and overall survival when used in conjunction with chemotherapy for early stage HER2- positive breast cancer. Despite adjuvant trastuzumab, approximately 15% of patients with early stage disease recur, and those with metastatic disease eventually become resistant to therapy. Novel treatment approaches are needed for patients who have either intrinsic or acquired resistance to trastuzumab. This article reviews the role of trastuzumab in managing early and advanced stage HER2-positive disease, the role of lapatinib (Tykerb®) in trastuzumab resistant disease, and the novel agents in development targeting mechanisms of trastuzumab resistance.
Export Options
About this article
Cite this article as:
Nanda Rita, Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions, Reviews on Recent Clinical Trials 2007; 2 (2) . https://dx.doi.org/10.2174/157488707780599375
DOI https://dx.doi.org/10.2174/157488707780599375 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer
MicroRNA Cytotoxic Constituents from the Bark of Erythrina poeppigiana Against the MCF-7 Breast Cancer Cell Lines
The Natural Products Journal Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Treatment of Acute Hypercalcemia
Medicinal Chemistry Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy miRNA 21: Diagnostic Prognostic and Therapeutic Marker for Oral Cancer
MicroRNA Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry